Polymorphism and solvatomorphism 2007

Journal of Pharmaceutical Sciences

Volumn 98, Issue 5, 2009, Pages 1617-1642

  Brittain, Harry G ^a  

^a Center for Pharmaceutical Physics   (United States)

Author keywords

Crystal structure; Physical characterization; Physicochemical properties; Polymorphism; Preformulation; Solid state; Solvation

Indexed keywords

10,11 DIHYDROCARBAMAZEPINE; 2 PROPANOL; ACEMETACIN; ALPRAZOLAM; BACLOFEN; BETA RESORCYLIC ACID; BICALUTAMIDE; BRUCINE; BUSPIRONE; BUTETHAL; CARBAMAZEPINE; CARBONIC ACID; CARVEDILOL; CHLOROTHIAZIDE; EPLERENONE; ERYTHROMYCIN; HYPOXANTHINE; NAPROXEN; NEVIRAPINE; PALONOSETRON; PARACETAMOL; PHENYLACETYLENE; QUINIDINE; SALBUTAMOL SULFATE; SULFAPYRIDINE; TAMOXIFEN CITRATE; TETRAHYDROFURAN; THEOPHYLLINE; UNCLASSIFIED DRUG; UNINDEXED DRUG; ZOLMITRIPTAN;

CARBON NUCLEAR MAGNETIC RESONANCE; CRYSTAL STRUCTURE; CRYSTALLOGRAPHY; DIFFERENTIAL SCANNING CALORIMETRY; DRUG SOLUBILITY; HYDROGEN BOND; MEDICAL LITERATURE; MOLECULAR MODEL; POLYMORPHISM; RAMAN SPECTROMETRY; REVIEW; SOLVATOMORPHISM; X RAY POWDER DIFFRACTION;

EID: 65949088359     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.21518     Document Type: Review

References (249)

1. Byrn SR, Pfeiffer RR, Stowell JG. 1999. Solid state chemistry of drugs. 2nd edition. West Lafayette: SSCI Inc.
2. Brittain HG. 1999. Polymorphism in pharmaceutical solids. New York: Marcel Dekker.
3. Bernstein J. 2002. Polymorphism in molecular crystals. Oxford: Clarendon Press.
4. Hilfiker R. 2006. Polymorphism in the pharmaceutical industry. Weinheim: Wiley-VCH.
5. Brittain HG, editor. 2005. Polymorphism and solvatomorphism 2004. In: Profiles of drug substances, excipients, and related methodology, Vol.32. Amsterdam: Elsevier Academic Press. pp 263-283.
6. Brittain HG. 2007. Polymorphism and solvatomorphism 2005. J Pharm Sci 96:705-728.
7. Brittain HG. 2008. Polymorphism and solvatomorphism 2006. J Pharm Sci DOI: 10.1002/jps.21274.
8. Cui Y. 2007. A material science perspective of pharmaceutical solids. Int J Pharm 339:3-18.
9. Gavezzotti A. 2007. A solid-state chemist's view of the crystal polymorphism of organic compounds. J Pharm Sci 96:2232-2241.
10. Stahly GP. 2007. Diversity in single- and multiple-component crystals. The search for and prevalence of polymorphs and cocrystals. Cryst Growth Des 7:1007-1026.
11. Baburin IA, Blatov VA. 2007. Three-dimensional hydrogen-bonded frameworks in organic crystals: A topological study. Acta Cryst B63:791-802.
12. Galek PTA, Fábián L, Motherwell WDS, Allen FH, Feeder N. 2007. Knowledge-based model of hydrogen-bonding propensity in organic crystals. Acta Cryst B63:768-782.
13. Podsiado M, Dziubek K, Katrusiak A. 2007. Pitfalls of data mining: Triclinic polymorph of 2,2-aziridinedicarboxamide revisited. Acta Cryst B63:118-123.
14. Harris RK. 2007. Applications of solid-state NMR to pharmaceutical polymorphism and related matters. J Pharm Pharmacol 59:225-239.
15. Zeitler JA, Taday PF, Newnham DA, Pepper M, Gordon KC, Rades T. 2007. Terahertz pulsed spectroscopy and imaging in the pharmaceutical setting. J Pharm Pharmacol 59:209-223.
16. Variankaval N, Sheth AR. 2007. Physical stability of crystal forms - Implications in drug development. Am Pharm Rev 10:96-101.
17. Bond AD, Boese R, Desiraju GR. 2007. What is a polymorph? Aspirin as a case study. Am Pharm Rev 10:24-30.
18. Sarsfield B, Davidovich M, DiMarco J, Galella M, Malley M, Pommier CJ, Yin S, Volk K. 2007. When spectroscopy is better than powder X-ray diffraction for crystal form analysis of active pharmaceutical ingredients. Am Pharm Rev 10:16-23.
19. Brown SC, Claybourn M, Fawcett V, Rodger C. 2007. Optimizing Raman spectroscopy to quantify polymorphic forms of a drug molecule. Am Pharm Rev 10:58-67.
20. Liang JK, Byrn S. 2007. On-line Raman spectroscopy in pharmaceutical process development: Application and future prospects. Am Pharm Rev 10:45-51.
21. Lara-Ochoa F, Espinosa-Pérez G. 2007. Crystals and patents. Cryst Growth Des 7:1213-1215.
22. Young PH, Ando HY. 2007. Analysis of known crystals to design polymorph prediction strategies. J Pharm Sci 96:1203-1236.
23. McKinnon JJ, Fabbiani FPA, Spackman MA. 2007. Comparison of polymorphic molecular crystal structures through Hirshfeld surface analysis. Cryst Growth Des 7:755-769.
24. Hammond RB, Pencheva K, Roberts KJ. 2007. Molecular modeling of crystal-crystal interactions between the α- and β-polymorphic forms of L-glutamic acid using grid-based methods. Cryst Growth Des 7:875-884.
25. Xu X-J, Zhu W-H, Xiao H-M. 2007. DFT studies on the four polymorphs of crystalline CL-20 and the influences of hydrostatic pressure on ε-CL-20 crystal. J Phys Chem B 111:2090-2097.
26. Li T. 2007. Understanding the polymorphism of aspirin with electronic calculations. J Pharm Sci 96:755-760.
27. Deij MA, ter Horst JH, Meekes H, Jansens P, Vlieg E. 2007. Polymorph formation studied by 3D nucleation simulations: Application to a yellow isoxazolone dye, paracetamol, and L-glutamic acid. J Phys Chem B 111:1523-1530.
28. Towler CS, Taylor LS. 2007. Spectroscopic characterization of intermolecular interactions in solution and their influence on crystallization outcome. Cryst Growth Des 7:633-638.
29. Perlovich GL, Hansen LK, Volkova TV, Mirza S, Manin AN, Bauer-Brandl A. 2007. Thermodynamic and structural aspects of hydrated and unhydrated phases of 4-hydroxy-benzamide. Cryst Growth Des 7:2643-2648.
30. Perlovich GL, Surov AO, Hansen LK, Bauer-Brandl A. 2007. Energetic aspects of diclofenac acid in crystal modifications and in solutions: Mechanism of solvation, partitioning, and distribution. J Pharm Sci 96:1031-1042.
31. van de Streek J, Motherwell WDS. 2007. New software for searching the Cambridge Structural Database for solvated and unsolvated crystal structures applied to hydrates. CrystEngComm 9:55-64.
32. Giroud N, Saal C, Wandschneider D, Maiwald M. 2007. Salt and polymorphism screening of high potency compounds: Modern methods and safe handling. Am Pharm Rev 10:89-95.
33. Aaltonen J, Strachan CJ, Pöllänen K, Yliruusi J, Rantanen J. 2007. Hyphenated spectroscopy as a polymorph screening tool. J Pharm Biomed Anal 44:477-483.
34. Anderton C. 2007. A valuable technique for polymorph screening. Am Pharm Rev 10:34-40.
35. Johnston A, Florence AJ, Shankland N, Kennedy AR, Shankland K, Price SL. 2007. Crystallization and crystal energy landscape of hydrochlorothiazide. Cryst Growth Des 7:705-712.
36. Xu D, Redman-Furey N. 2007. Statistical cluster analysis of pharmaceutical solvents. Int J Pharm 339:175-188. (Pubitemid 46977606)
37. Dematos LL, Williams AC, Booth SW, Petts CR, Taylor DJ, Blagden N. 2007. Solvent influences on metastable polymorph lifetimes: Real-time interconversions using energy dispersive X-ray diffractometry. J Pharm Sci 96:1069-1078.
38. Xu M, Harris KDM. 2007. Alteration of polymorphic selectivity through different crystallization mechanisms occurring in the same crystallization solution. J Phys Chem B 111:8705-8707. (Pubitemid 47317445)
39. Burley JC, Duer MJ, Stein RS, Vrceljb RM. 2007. Enforcing Ostwald's rule of stages: Isolation of paracetamol forms III and II. Eur J Pharm Sci 31:271-276.
40. Tao J, Jones KJ, Yu L. 2007. Cross-nucleation between D-mannitol polymorphs in seeded crystallization. Cryst Growth Des 7:2410-2414.
41. Wu T, Yu L. 2007. Origin of enhanced crystal growth kinetics near Tg probed with indomethacin polymorphs. J Phys Chem B 111:15694-15699.
42. Chen JW, Black SN, Chow PS, Tan RBH, Carpenter KJ. 2007. Stable polymorphs: Difficult to make and difficult to predict. CrystEngComm 9:128-130.
43. Fabbiani FPA, Allan DR, David WIF, Davidson AJ, Lennie AR, Parsons S, Pulham CR, Warren JE. 2007. High-pressure studies of pharmaceuticals: An exploration of the behavior of piracetam. Cryst Growth Des 7:1115-1124.
44. Du-Cuny L, Huwyler J, Fischer H, Kansy M. 2007. A potentiometric titration method for the crystallization of drug-like organic molecules. Int J Pharm 342:161-167.
45. Varshney DB, Kumar S, Shalaev EY, Sundaramurchi P, Kang S-W, Gatlin LA, Suryanarayanan R. 2007. Glycine crystallization in frozen and freeze-dried systems: Effect of pH and buffer concentration. Pharm Res 24:593-604.
46. Fioritto AF, Bhattachar SN, Wesley JA. 2007. Solubility measurement of polymorphic compounds via the pH-metric titration technique. Int J Pharm 330:105-113.
47. Seadeek C, Ando H, Bhattachar SN, Heimback T, Sonnenberg JL, Blackburn AC. 2007. Automated approach to couple solubility with final pH and crystallinity for pharmaceutical discovery compounds. J Pharm Biomed Anal 43:1660-1666.
48. Bouchard A, Jovanović N, Hofland GW, Mendes E, Crommelin DJA, Jiskook W, Witkamp G-J. 2007. Selective production of polymorphs and pseudomorphs using supercritical fluid crystallization from aqueous solutions. Cryst Growth Des 7:1432-1440.
49. Park HJ, Kim M-S, Lee S, Kim J-S, Woo J-S, Park J-S, Hwang S-J. 2007. Recrystallization of fluconazole using the supercritical antisolvent (SAS) process. Int J Pharm 328:152-160.
50. Grezesiak AL, Matzger AJ. 2007. New form discovery for the analgesics flurbiprofen and sulindac facilitated by polymer-induced heteronucleation. J Pharm Sci 96:2978-2986.
51. Dressler DH, Mastai Y. 2007. Controlling polymorphism by crystallization on self-assembled multilayers. Cryst Growth Des 7:847-850.
52. Godec A, Maver U, Bele M, Planinšek O, Srčič S, Gaberšček M, Jamnik J. 2007. Vitrification from solution in restricted space: Formation and stabilization of amorphous nifedipine in a nanoporous silica xerogel carrier. Int J Pharm 343:131-140.
53. Di Profio G, Tucci S, Curcio E, Drioli E. 2007. Selective glycine polymorph crystallization by using microporous membranes. Cryst Growth Des 7:526-530.
54. Lu F, Zhou G, Zhai H-J, Wang Y-B, Wang H-S. 2007. Nucleation and growth of glycine crystals with controllable sizes and polymorphs on Langmuir-Blodgett films. Cryst Growth Des 7:2654-2657.
55. Capes JS, Cameron RE. 2007. Contact line crystallization to obtain metastable polymorphs. Cryst Growth Des 7:108-112.
56. Lancaster RW, Karamertzanis PG, Hulme AT, Tocher DA, Lewis TC, Price SL. 2007. The polymorphism of progesterone: Stabilization of a 'disappearing' polymorph by co-crystallization. J Pharm Sci 96:3419-3431.
57. Kelleher JM, Lawrence SE, McAuliffe MT, Moynihan HA. 2007. Monomeric and polymeric derivatives of 5-aminoisophthalic acid as selective inhibitors of the b-polymorph of L-glutamic acid. CrystEngComm 9:72-77.
58. Ledru J, Imrie CT, Pulham CR, Cécaron;olin R, Hutchinson JM. 2007. High pressure differential scanning calorimetry investigations on the pressure dependence of the melting of paracetamol polymorphs I and II. J Pharm Sci 96:2784-2794.
59. Kachrimanis K, Braun DE, Greisser UJ. 2007. Quantitative analysis of paracetamol polymorphs in powder mixtures by FT-Raman spectroscopy and PLS regression. J Pharm Biomed Anal 43:407-412.
60. Sheikhzadeh M, Rohani S, Taffish M, Murad S. 2007. Solubility analysis of buspirone hydrochloride polymorphs: Measurements and prediction. Int J Pharm 338:55-63.
61. Sheikhzadeh M, Rohani S, Jutan A, Manifar T. 2007. Quantitative and molecular analysis of buspirone hydrochloride polymorphs. J Pharm Sci 96:569-583.
62. Strachan CJ, Rades T, Gordon KC. 2007. A theoretical and spectroscopic study of γ-crystalline and amorphous indomethacin. J Pharm Pharmacol 59:261-269.
63. Heinz A, Savolainen M, Rades T, Strachan CJ. 2007. Quantifying ternary mixtures of different solid-state forms of indomethacin by Raman and near-infrared spectroscopy. Eur J Pharm Sci 32:182-192.
64. Harding L, King WP, Dai X, Craig DQN, Reading M. 2007. Nanoscale characterization and imaging of partially amorphous materials using local thermomechanical analysis and heated tip AFM. Pharm Res 24:2048-2054.
65. De Armas H, Peeters OM, van den Mooter G, Blaton N. 2007. Polymorphism of alprazolam (Xanax®): A review of its crystalline phase and identification, crystallographic characterization, and crystal structure of a new polymorphs (Form III). J Pharm Sci 96:1114-1130.
66. Vega DR, Polla G, Martinez A, Mendioroz E, Reinoso M. 2007. Conformational polymorphism in bicalutamide. Int J Pharm 328:112-118.
67. Gelbrich T, Threlfall TL, Bingham AL, Hursthouse MB. 2007. Polymorph VI of sulfapyridine: Interpenetrating two- and three-dimensional hydrogen-bonded nets formed from two tautomeric forms. Acta Cryst C63:o323-o326.
68. Yathirajan HS, Bindya S, Sreevidya TV, Narayana B, Bolte M. 2007. A second polymorph of carvedilol. Acta Cryst E63:o524-o544.
69. Ravikumar K, Sridhar B. 2007. An orthorhombic polymorph of palonosetron hydrochloride. Acta Cryst E63:o1404-o1406.
70. Leech CK, Florence AJ, Shankland K, Shankland N, Johnston A. 2007. 10,11-dihydrocarbamazepine (form III). Acta Cryst E63:o675-o677.
71. Threlfall TL, Gelbrich T. 2007. The crystal structure of methyl paraben at 118 K does not represent a new polymorph. Cryst Growth Des 7:2297.
72. Tiwari M, Chawla G, Bansal AK. 2007. Quantification of olanzapine polymorphs using powder Xray diffraction technique. J Pharm Biomed Anal 43:865-872.
73. De Spiegeleer B, Baert B, Diericx N, Seghers D, Verpoort F, van Vooren L, Burvenich C, Glegers G. 2007. Assessment of the solid-state composition of an active salicylanilide compound by FT-Raman spectroscopy. J Pharm Biomed Anal 44:254-257.
74. 13C NMR spectroscopy. Cryst Growth Des 7:1406-1410.
75. Palacio MA, Cuffini S, Badini R, Karlsson A, Palacios SM. 2007. Solid-state characterization of two polymorphic forms of R-albuterol sulfate. J Pharm Biomed Anal 43:1531-1534.
76. Kojima T, Onoue S, Katoh F, Teraoka R, Matsuda Y, Kitagawa S, Tsuhako M. 2007. Effect of spectroscopic properties on photostability of tamoxifen citrate polymorphs. Int J Pharm 336:346-351.
77. Hulme AT, Johnston A, Florence AJ, Fernandes P, Shankland K, Bedford CD, Welch GWA, Sadiq G, Haynes DA, Motherwell WDS, Tocher DA, Price SL. 2007. Search for a predicted hydrogen bond motif: A multidisciplinary investigation into the polymorphism of 3-azabicyclo[3.3.1]nonane-2,4-dione. J Am Chem Soc 129:3649-3657.
78. Dziubek K, Podsiadło M, Katrusiak A. 2007. Nearly isostructural polymorphs of ethnylbenzene: Resolution of CHp(arene) and cooperative CHp(CC) interactions by pressure freezing. J Am Chem Soc 129:12620-12621.
79. Winkel K, Hage W, Loerting T, Price SL, Mayer E. 2007. Carbonic acid: From polyamorphism to polymorphism. J Am Chem Soc 129:13863-13871.
80. 10 helix dimorphism in the crystal state. J Am Chem Soc 129:15471-15473.
81. Reichelt H, Faunce CA, Paradies HH. 2007. Elusive forms and structures of N-hydroxy-phthalimide: The colorless and yellow crystal forms of N-hydroxyphthalimide. J Phys Chem A 111:2587-2601.
82. Senju T, Nishimura N, Mizuguchi J. 2007. Polymorph of 2,9-dichloroquinacridone and its electronic properties. J Phys Chem A 111:2966-2970.
83. Schmidt HLF, Sperling LJ, Gao YG, Wylie BJ, Boettcher JM, Wilson SR, Rienstra CM. 2007. Crystal polymorphism of protein GB1 examined by solid-state NMR spectroscopy and X-ray diffraction. J Phys Chem B 111:14362-14369.
84. Hara T, Hayashi Y, Kitamura M. 2007. Effect of the alkyl group in BPT-esters on the polymorphic crystallization behavior. Cryst Growth Des 7:147-152.
85. Cohen DE, Benedict JB, Morlan B, Chiu DT, Kahr B. 2007. Dyeing polymorphs: The MALDI host 2,5-dihydroxybenzoic acid. Cryst Growth Des 7:492-495.
86. Roy S, Nangia A. 2007. Kinetic and thermodynamic conformational polymorphs of bis(p-tolyl) ketone p-tosyl-hydrazone: The Curtin-Hammett principle in crystallization. Cryst Growth Des 7:2047-2058.
87. Xie Z, Wang H, Li F, Xie W, Liu L, Yang B, Ye L, Ma Y. 2007. Crystal structure of a highly luminescent slice crystal grown in the vapor phase: A new polymorph of 2,5-diphenyl-1,4-disyrylbenzene. Cryst Growth Des 7:2512-2516.
88. Gdaniec M. 2007. On the polymorphs of penta- fluorophenol and its 2:1 co-crystal with pentafluoroaniline. CrystEngComm 9:286-288.
89. Warde SMSV, de Souza MVN, Wardell JL, Low JN, Glidewell CB. 2007. Three isomeric 1-(2-chloronicotinoyl)- 2-(nitrophenyl)hydrazines, including three polymorphs of 1-(2-chloronicotinoyl)-2-(nitrophenyl)hydrazine: Hydrogen-bonded supramolecular structures in two and three dimensions. Acta Cryst B63:101-110.
90. Parkin A, Adam M, Cooper RI, Middlemiss DS, Wilson CC. 2007. Structure and hydrogen bonding in 2,4-dihydroxybenzoic acid at 90, 100 110, and 150 K: A theoretical and single-crystal X-ray diffraction study. Acta Cryst B63:303-308.
91. Jones NA, Jenkinson SF, Soengas R, Izumori K, Fleet GWJ, Watkin DJ. 2007. The concomitant crystallization of two polymorphs of 1-deoxy-α-D- tagatose. Acta Cryst C63:o7-o10.
92. Gotoh K, Asaji T, Ishida H. 2007. Hydrogen bonding in two solid phases of phenazine-chloranilic acid (1/1) determined at 170 and 93 K. Acta Cryst C63:o17-o20.
93. Coles SJ, Davies DB, Hacivelioǧlu F, Hursthouse MB, Ibişoǧlu H, Kiliç, Shaw RA. Dimorphism in 4,4,6,6-tetrachloro-2,2-(2,2-dimethylpropane-1, 3-dioxy)-cyclotriphosphazene and 6,6-dichloro2,2: 4,4-bis(2,2-dimethylpropane-1,3-dioxy)-cyclotriphosphazene. Acta Cryst C63:o152-o156.
94. Weigand JJ, Davidson RJ, Cameron TS, Burford N. 2007. A second polymorph of bis(dimethylphosphino) dimethylphosphonium trifluoromethanesulfonate. Acta Cryst C63:o193-o195.
95. Wardell JL, Howie RA, Low JN, Glidewell C. 2007. A re-examination of supramolecular aggregation in two polymorphs of acetone 2,4- dinitrophenylhydrazone. Acta Cryst C63:o231-o233.
96. Drebushchak TN, Chukanov NV, Boldyreva EV. 2007. A new g-polymorph of chlorpropamide: 4-chloro-N-(propylaminocarbonyl)benzenesulfonamide. Acta Cryst C63:o355-o357.
97. Mague JT, Balakrishna MS, Punji B, Suresh D. 2007. Two crystal modifications of 1,1′-thiobis(2-naphthol). Acta Cryst C63:o487-o488.
98. Ramos-Organillo A, Contreras R. 2007. A new sulfate acid polymorph of 1,3-dihydro-benzotriazole. Acta Cryst C63:o501-o503.
99. Athimoolam S, Natarajan S. 2007. 4-carboxyanilinium (2R,3R)-tartrate and a redetermination of the α-polymorph of 4-aminobenzoic acid. Acta Cryst C63:o514-o517.
100. Ojala CR, Ojala WH, Britton D, Cramer CJ. 2007. Three polymorphs of 4,4′-diiodo-benzalazine and 4-chloro-40-iodo benzalazine. Acta Cryst C63:o518-o523.
101. Kubone K, Yokoi K. 2007. Monoclinic and orthorhombic polymorphs of 4,4′,6,6′-tetrachloro-2,2′-(piperazine-1,4-diyldimethylene) -diphenol. Acta Cryst C63:o535-o537.
102. Kaufmann L, Lerner H-W, Bolte M. 2007. A new polymorph of tetraphenyl-diboroxane. Acta Cryst C63:o588-o590.
103. Roshal AD, Sikorski A, Baumer VN, Novikov AI, Błażejowski J. 2007. Two polymorphs of 2-(4-chlorophenyl)-4-methylchromnium perchlorate. Acta Cryst C63:o626-o630.
104. Gelbrich T, Zencirci N, Griesser UJ. 2007. A polymorph of butobarbital with two distinct hydrogen-bonding motifs. Acta Cryst C63:o751-o753.
105. Nazir U, Zareen A, Bolte M, Butt S, Siddiqi HM. 2007. A new triclinic polymorph of 4-n-hexyl-oxybenzoic acid. Acta Cryst E63:o12-o14.
106. Eltayeb NE, Teoh SG, Teh JB-J, Fun K-K, Ibrahim K. 2007. Second monoclinic polymorph of 2-(benzimidazol-2-yl)-6-methoxyphenol. Acta Cryst E63:o300-o302.
107. Yildirim SÖ, Akkurt M, Özpozan T, Heinemann FW. 2007. Orthorhombic polymorph of 1,2-bis(2-aminophenoxy)ethane. Acta Cryst E63:o331-o332.
108. Khan U, Qureshi RA, Saeed S, Bond AD. 2007. An orthorhombic polymorph of myo-inositol. Acta Cryst E63:o530-o532.
109. Nesterov VN, Sarkisov SS, Curley MJ, Urbas A. 2007. An orthorhombic polymorph of 3,5-bis[4-(dimethylamino)benzylidene]-1-methyl-4-piperidone. Acta Cryst E63:o1785-o1787.
110. Tewari AK, Singh VP, Puerta C, Valerga P. 2007. A new polymorph of 4,4′-(ethylene-dioxy)-dibenzaldehyde. Acta Cryst E63:o1930-o1931.
111. Entwistle CD, Batsanov AS, Marder TB. 2007. A new polymorph of dimesitylborinic acid. Acta Cryst E63:o2639-o2641.
112. Yamashita M, Inomata S, Ishikawa K, Kashiwagi T, Matsuo H, Sawamura S, Kato M. 2007. A high-pressure polymorph of L-α-leucine. Acta Cryst E63:o2762-o2764.
113. Schuck G, Haas S, Stassen AF, Berens U, Batlogg B. 2007. 5,11-bis(4-tert-butyl-phenyl)-6,12-diphenylnephthacene (form A). Acta Cryst E63:o2894.
114. Małecki JG, Kruszynski R, Kusz J. 2007. The orthorhombic polymorph of pyrazine-2-carboxylic acid revisited. Acta Cryst E63:o3300.
115. Yang R-Q, Xie Y-R. 2007. A monoclinic polymorph of hypoxanthine. Acta Cryst E63:o3309.
116. Eltayeb NE, Teoh SG, Chantrapromma S, Fun HK, Ibrahim K. 2007. A second monoclinic polymorph of 5,6-diphenyl-3-(2-pyridyl)-1,2,4-triazine. Acta Cryst E63:o3792-o3793.
117. Sparkes HA, Howard JAK. 2007. Coumarin-3-carboxylic acid: A second P21/c modification. Acta Cryst E63:o3894.
118. Sparkes HA, Howard JAK. 2007. 3-(bromoacetyl)-coumarin: A second P21/c modification. Acta Cryst E63:o3895.
119. Nichol GS, Clegg W. 2007. A second C2/c polymorph of butobarbitone. Acta Cryst E63:o4147.
120. Zhang Q-C, Shu Z, Shen L, Wang Q, Jin Z-M. 2007. A second polymorph of 1-(carboxymethyl)-5-fluorouracil. Acta Cryst E63:o4214.
121. Tong H-B, Zhou M-S, Bi Q-X, Chao J-B. 2007. A new polymorph of N,N-dibenzylaniline. Acta Cryst E63:o4560.
122. Brewer G, Jasinski JP, Butcher RJ, Scheidt WR. 2007. N,N′-bis(2- acetylphenyl) ethanediamide. Acta Cryst E63:o4887-o4888.
123. Brewer G, Jasinski JP, Butcher RJ, Scheidt WR. 2007. N,N′-bis(2- acetylphenyl) ethanediamide, a second polymorph. Acta Cryst E63:o4889.
124. Strzhemechny MA, Baumer VN, Avdeenko AA, Pyshkin OS, Romanshkin RV, Buravtseva LM. 2007. Polymorphism of 4-bromobenzophenone. Acta Cryst B63:296-302.
125. Infantes L, Fábián L, Motherwell WDS. 2007. Organic crystal hydrates: What are the important factors for formation. CrystEngComm 9:65-71.
126. Tian F, Zhang F, Sandler N, Gordon KC, McGoverin CM, Strachan CJ, Saville DJ, Rades T. 2007. Influence of sample characteristics on quantification of carbamazepine hydrate formation by X-ray powder diffraction and Raman spectroscopy. Eur J Pharm Biopharm 66:466-474.
127. Fernandes P, Bardin J, Johnston A, Florence AJ, Leech CK, David WIF, Shankland K. 2007. Carbamazepine trifluoroacetic acid solvate. Acta Cryst E63:o4269.
128. Johnston A, Florence AJ, Shankland K, Leech CK, Shankland N, Fernandes P. 2007. 10,11-dihydrocarbamazepine - Dimethyl sulfoxide (1/1). Acta Cryst E63:o3918-o3919.
129. Johnston A, Florence AJ, Fernandes P, Shankland N, Kennedy AR. 2007. 10,11-dihydrocarbamazepine - Formamide solvate (1/1). Acta Cryst E63:o3888-o3889.
130. Fernandes P, Shankland K, Florence AJ, Shankland N, Johnston A. 2007. Solving molecular crystal structures from X-ray powder diffraction data: The challenges posed by g-carbamazepine and chlorothiazide N,N-dimethylformamide (1/2) solvate. J Pharm Sci 96:1192-1202.
131. Johnston A, Florence AJ, Fernandes P, Kennedy AR. 2007. Chlorothiazide dimethyl sulfoxide solvate. Acta Cryst E63:o2423.
132. Fabbiani FPA, Leech CK, Shankland K, Johnston A, Fernandes P, Florence AJ, Shankland N. 2007. Hirshfeld surface analysis of two bendroflumethazide solvates. Acta Cryst C63:o659-o663.
133. Fernandes P, Johnston A, Leech CK, Shankland K, David WIF, Florence AJ. 2007. Hydroflumethiazide dimethyl sulfoxide disolvate. Acta Cryst E63:o3956.
134. Wang Z-L, Wei L-H. 2007. Theophylline - 2,4-dihydroxybenzoic acid-water (1/1/1). Acta Cryst E63:o1681-o1682.
135. Foppoli A, Zema L, Gazzaniga A, Caira MR, Nassimbeni LR, Borkum E, Bettini R, Giordano F. 2007. Solid-state chemistry of ambroxol theophylline-7-acetate. J Pharm Sci 96:1139-1146.
136. Cardin C, Gan Y, Lewis T. 2007. Low-temperature determination of theophylline dimethyl sulfoxide solvate. Acta Cryst E63:o3175.
137. Hickey MB, Peterson ML, Manas ES, Alvarez J, Haeffner F, Almarsson Ö. 2007. Hydrates and solid-state reactivity: A survey of b-lactam antibiotics. J Pharm Sci 96:1090-1099.
138. Henry R, Zhang GGZ. 2007. Crystallographic characterization of several erythromycin A solvates: The environment of the solvent molecules in the crystal lattice. J Pharm Sci 96:1251-1257.
139. di Martino P, Barthélémy C, Joiris E, Capsoni D, Masic A, Massarotti V, Gobetto R, Bini M, Martelli S. 2007. A new tetrahydrated form of sodium naproxen. J Pharm Sci 96:156-167.
140. Suitchmezian V, Jess I, Näther C. 2007. Investigation on the polymorphism and pseudo-polymorphism of the glucocorticoid triaamcinolone: New findings for a well-known drug. Cryst Growth Des 7:69-74.
141. Othman A, Evans JSO, Evans IR, Harris RK, Hodgkinson P. 2007. Structural study of polymorphs and solvates of finasteride. J Pharm Sci 96:1380-1397.
142. Mirza S, Miroshnyk I, Rantanen J, Aaltonen J, Harjula P, Kiljunen E, Heinämäki J, Yliruusi J. 2007. Solid-state properties and relationship between anhydrate and monohydrate of baclofen. J Pharm Sci 96:2399-2408.
143. Ravikumar K, Sridhar B, Krishnan H. 2007. Zolmitriptan, and antimigraine drug. Acta Cryst E63:o1774-o1776.
144. Sridhar B, Ravikumar K, Krishnan H. 2007. Zolmitriptan chloroform solvate. Acta Cryst E63:o1961-o1962.
145. Swamy GYSK, Sridhar B, Ravikumar K, Krishnan H. 2007. The 1:1 inclusion compounds zolmitriptan-benzene and zolmitriptan-phenol. Acta Cryst C63:o437-o440.
146. Kojima T, Kato F, Teraoka R, Matsuda Y, Kitagawa S, Tsuhako T. 2007. Physicochemical characterization of tamoxifen citrate pseudopolymorphs, methanolate and ethanolate. Chem Pharm Bull 55:407-411.
147. Caira MR, Bettinetti G, Sorrenti M, Catenacci L. 2007. Relationships between structural and thermal properties of anhydrous and solvated crystalline forms of brodimoprim. J Pharm Sci 96:996-1007.
148. Pereira BG, Fonte-Boa FD, Rescende JALC, Pinheiro CB, Fernandes NG, Yoshida MI, Vianna-Soares CD. 2007. Pseudopolymorphs and intrinsic dissolution of nevirapine. Cryst Growth Des 7:2016-2023.
149. Liu H-B, Chen Y, Zhang X-C. 2007. Characterization of anhydrous and hydrated pharmaceutical materials with THz time-domain spectroscopy. J Pharm Sci 96:927-934.
150. Kirk JH, Dann SE, Blatchford CG. 2007. Lactose: Adefinitive guide to polymorph determination. Int J Pharm 334:103-114.
151. Lekshmi NS, Pedireddi VR. 2007. Solid-state structures of 4-carboxyphenylboronic acid and its hydrates. Cryst Growth Des 7:944-949.
152. Grossel MC, Dwyer AN, Hursthouse MB, Orton JB. 2007. Solid-state assemblies from pyridine-2,6-dicarboxylates: Changing the instruction set through hydration. CrystEngComm 9:207-210.
153. Gagnon E, Maly K, Maris T, Wuest JD. 2007. A new pseudopolymorph of hexakis-(4-cyanophenyl) benzene. Acta Cryst C63:o4-o6.
154. Guille K, Harrington RW, Clegg W. 2007. Violuric acid monohydrate: A second polymorph with more extensive hydrogen bonding. Acta Cryst C63:o327-o329.
155. Gelbrich T, Haddow MF, Griesser UJ. 2007. Acemetacin monohydrate. Acta Cryst C63:o451-o453.
156. Smith G, Wermuth UD, White JM. 2007. Pseudo-polymorphism in brucine: Brucine-water (1/2), the third crystal hydrate of brucine. Acta Cryst C63:o489-o492.
157. Smith G, Wermuth UD, White JM. 2007. 1,10-phenanthrolin-1-ium pamoate N,N-dimethylformamide solvate. Acta Cryst E63:o506-o508.
158. Johnston A, Florence AJ, Fernandes P, Shankland N, Kennedy AR. 2007. 10,11-dihydrocarbamazepine formic acid solvate. Acta Cryst E63:o1469-o1470.
159. Guo M-J, Zhang S-J, Sun D-L, Fan Z. 2007. Quinidine sesquihydrate. Acta Cryst E63:o1483-o1484.
160. Chantrapromma S, Boonnak N, Fun H-K, Karalai C. 2007. Artocarpin dichloromethane hemisolvate. Acta Cryst E63:o1864-o1866.
161. Athikomrattanakul U, Promptmas C, Katterle M, Schilde U. 2007. An orthorhombic polymorph of melaminium chloride hemihydrate. Acta Cryst E63:o2154-o2156.
162. Zhao H. 2007. 3-ammonio-3-(4-pyridyl) propanoate dihydrate. Acta Cryst E63:o3400.
163. Grigoriev MS, Pisareva SA, Safiulina AM, Nifant'ev EE. 2007. 1,1,1-tris[(diphenyl-phosphoryl) methyl]-propane monohydrate. Acta Cryst E63:o3441.
164. Kaluderović GN, Gómez-Ruiz S, Schmidt H, Steinborn D. 2007. N,N,N′,N′-tetrakis(carboxy methyl) ethylenediammonium dichloride trihydrate. Acta Cryst E63:o3491.
165. Shankland K, Leech CK, Mohamed S, Barnett SA, Tocher DA. 2007. 7-fluoroisatin - 1,4-dioxane (1/1). Acta Cryst E63:o3574.
166. Mohamed S, Barnett SA, Tocher DA. 2007. 7-fluoroisatin - Dimethyl sulfoxide (1/1). Acta Cryst E63:o3575.
167. Mohamed S, Barnett SA, Tocher DA. 2007. 5-fluoroisatin - Dimethyl sulfoxide (1/1). Acta Cryst E63:o3576.
168. Lin M, Liu S-X. 2007. A new polymorph of 2′-(4- methoxybenzlidene) isonicotino hydrazide monohydrate. Acta Cryst E63:o3974.
169. Johnston A, Florence AJ, Kennedy AR. 2007. Chlorothiazide formic acid solvate (1/2). Acta Cryst E63:o4021.
170. Suitchmezian V, Jess I, Näther C. 2007. Betamethasone-21-pentanoate methanol solvate. Acta Cryst E63:o4839.
171. Xu L-Z, Yang Q, Nie J-J. 2007. Eplerenone 1,4-dioxane solvate. Acta Cryst E63:o4898.
172. Kawakami K. 2007. Reversibility of enantiotropically related polymorphic transformations from a practical viewpoint: Thermal analysis of kinetically reversible/irreversible polymorphic transformations. J Pharm Sci 96:982-989.
173. Legendre B, Randzio SL. 2007. Transitiometric analysis of solid II/solid I transition in anhydrous theophylline. Int J Pharm 343:41-47.
174. Matsuo K, Matsuoka M. 2007. Solid-state polymorphic transition of theophylline anhydrate and humidity effect. Cryst Growth Des 7:411-415.
175. Amado AM, Nolasco MM, Ribeiro-Claro PJA. 2007. Probing pseudopolymorphic transitions in pharmaceutical solids using Raman spectroscopy: Hydration and dehydration of theophylline. J Pharm Sci 96:1366-1379.
176. Zeitler JA, Kogermann K, Rantanen J, Rades T, Taday PF, Pepper M, Aaltonen J, Strachan CJ. 2007. Drug hydrate systems and dehydration processes studied by terahertz pulsed spectroscopy. Int J Pharm 344:78-84.
177. Qu H, Louhi-Kultanen M, Kallas J. 2007. Additive effects on the solvent-mediated anhydrate/hydrate phase transformation in a mixed solvent. Cryst Growth Des 7:724-729.
178. Tian F, Saville DJ, Gordon K, Strachan CJ, Zeitler JA, Sandler N, Rades T. 2007. The influence of various excipients on the conversion kinetics of carbamazepine polymorphs in aqueous suspension. J Pharm Pharmacol 59:193-201.
179. Wildfong PLD, Morris KM, Anderson CA, Short SM. 2007. Demonstration of a shear-based solid-state phase transformation in a small molecular organic system: Chlorpropamide. J Pharm Sci 96:1100-1113. (Pubitemid 46797480)
180. Roy S, Bhatt PM, Nangia A, Kruger GJ. 2007. Stable polymorph of venlafaxine hydrochloride by solid-to-solid phase transition at high temperature. Cryst Growth Des 7:476-480.
181. Sheikhzadeh M, Murad S, Rohani S. 2007. Response surface analysis of solution-mediated polymorphic transformation of buspirone hydrochloride. J Pharm Biomed Anal 45:227-236.
182. Hu Y, Wikström H, Syrn SR, Taylor LS. 2007. Estimation of the transition temperature for an enantiotropic polymorphic system from the transformation kinetics monitored using Raman spectroscopy. J Pharm Biomed Anal 45:546-551.
183. Gift AD, Taylor LS. 2007. Hyphenation of Raman spectroscopy with gravimetric analysis to interrogate water-solid interactions in pharmaceutical systems. J Pharm Biomed Anal 43:14-26.
184. Kryzyaniak JF, Williams GR, Ni N. 2007. Identification of phase boundaries in anhydrate/hydrate systems. J Pharm Sci 96:1270-1281.
185. Brittain HG. 2007. Fluorescence studies of the dehydration of cefadroxil monohydrate. J Pharm Sci 96:2757-2764.
186. Reddy VR, Rajmohan MA, Shilpa RL, Raut DM, Naveenkumar K, Suryanarayana MV, Mathad VT. 2007. A novel quantification method of pantoprazole sodium monohydrate in sesquihydrate by thermogravimetric analyzer. J Pharm Biomed Anal 43:1836-1841.
187. Bates S, Kelly RC, Ivanisevic I, Schields P, Zografi G, Newman AW. 2007. Assessment of defects and amorphous structure produced in raffinose pentahydrate upon dehydration. J Pharm Sci 96:1418-1433.
188. Zhang TH, Liu XY. 2007. How does a transient amorphous precursor template crystallization. J Am Chem Soc 129:13520-13526.
189. Yamamura S, Takahira R, Momose Y. 2007. Crystallization kinetics of amorphous griseofulvin by pattern fitting procedure using X-ray diffraction data. Pharm Res 24:880-887.
190. Zeitler JA, Taday PF, Pepper M, Rades T. 2007. Relaxation and crystallization of amorphous carbamazepine studied by terahertz pulsed spectroscopy. J Pharm Sci 96:2703-2709.
191. Vyazovkin S, Dranca I. 2007. Effect of physical aging on nucleation of amorphous indomethacin. J Phys Chem B 111:7283-7287.
192. Li H, Stowell JG, He X, Morris KR, Byrn SR. 2007. Investigations on solid-solid phase transformation of 5-methyl-2-[(4-methyl-2-nitrophenyl)amino]- 3-thiophenecarbonitrile. J Pharm Sci 96:1079-1089.
193. Anwar J, Tuble SC, Kendrick J. 2007. Concerted molecular displacements in a thermally-induced solid-state transformation in crystals of DL-norleucine. J Am Chem Soc 129:2542-2547.
194. Beckham GT, Peters B, Starbuck C, Variankaval N, Trout BL. 2007. Surface-mediated nucleation in the solid-state polymorph transformation of terephthalic acid. J Am Chem Soc 129:4714-4723.
195. Wemhoff AP, Burnham AK, Nichols AL III. 2007. Application of global kinetic models to HMX β-δ transition and cookoff process. J Phys Chem A 111:1574-1584.
196. Dreger ZA, Gupta YM. 2007. High pressure Raman spectroscopy of single crystals of hexahydro-1,3,5-trinitro-1,3,5-triazine (RDX). J Phys Chem B 111:3893-3903.
197. de Souza JM, Freire PTC, Bordallo HN, Arfyriou DN. 2007. Structural isotopic effects in the smallest chiral amino acid: Observation of a structural phase transition in fully deuterated alanine. J Phys Chem B 111:5034-5039.
198. Paukov IE, Kovalevskaya YA, Drebushchak VA, Drebushchak TN, Boldyreva EV. 2007. An extended phase transition in crystalline L-cysteine near 70 K. J Phys Chem B 111:9186-9188.
199. Levitas VI, Henson BF, Smilowitz LB, Asay BW. 2007. Solid-solid phase transformation via internal stress-induced virtual melting, significantly below the melting temperature: Application to HMX energetic crystal. J Phys Chem 111:10105-10119.
200. Patterson JE, Dreger ZA, Gupta YM. 2007. Shock wave-induced phase transition in RDX single crystals. J Phys Chem B 111:10897-10904.
201. Banerji A, Deb SK. 2007. Raman scattering study of high-pressure phase transition in thiourea. J Phys Chem B 111:10915-10919.
202. Kavitha G, Narayana C. 2007. Raman spectroscopic investigations of pressure-induced phase transitions in n-hexane. J Phys Chem B 111:14130-14135.
203. Schwahn D, Ma Y, Cölfen H. 2007. Mesocrystal to single crystal transformation of D,L-alanine evidenced by small angle neutron scattering. J Phys Chem C 111:3224-3227.
204. Heinrich MA, Pflaum J, Tripathi AK, Frey W, Steigerwald ML, Siegrist T. 2007. Enantiotropic polymorphism in di-indeneoperylene. J Phys Chem C 111:18878-18881.
205. Gray J, Nicholls M. 2007. The influence of morphic form on formulation design. Am Pharm Rev 10:90-95.
206. Yamada H, Suryanarayanan R. 2007. X-ray powder diffractometry of intact film coated tablets: An approach to monitor the physical form of the active pharmaceutical ingredient during processing and storage. J Pharm Sci 96:2029-2036.
207. Tian F, Sandler N, Aaltonen J, Lang C, Saville DJ, Gordon KC, Strachan CJ, Rantanen J, Rades T. 2007. Influence of polymorphic form, morphology, and excipient interactions on the dissolution of carbamazepine compacts. J Pharm Sci 96:584-594.
208. Li X, Zhi F, Hu Y. 2007. Investigation of excipient and processing on solid phase transformation and dissolution of ciprofloxacin. Int J Pharm 328:177-182.
209. Tantry JS, Tank J, Suryanarayanan R. 2007. Processing-induced phase transitions of theophylline: Implications on the dissolution of theophylline tablets. J Pharm Sci 96:1434-1444.
210. Descamps M, Willart JF, Dudognon E, Caron V. 2007. Transformation of pharmaceutical compounds upon milling and comilling: The role of Tg. J Pharm Sci 96:1398-1407.
211. Picker-Freyer KM, Liao X, Zhang G, Wiedmann TS. 2007. Evaluation of the compaction of sulfathiazole polymorphs. J Pharm Sci 96:2111-2124.
212. Di Martine P, Censi R, Barthélémy C, Gobetto R, Joiris E, Masic A, Odou P, Martelli S. 2007. Characterization and compaction behavior of nimesulide crystal forms. Int J Pharm 342:137-144.
213. Römer M, Heinämäki J, Miroshnyk I, Sandler N, Rantanen J, Yliruusi J. 2007. Phase transformations of erythromycin A dihydrate during pelletization and drying. Eur J Pharm Biopharm 67:246-252.
214. Wang X, de Armas HN, Blaton N, Michoel A, Van den Mooter G. 2007. Phase characterization of indomethacin in binary solid dispersions with PVP VA64 or Myrj 52. Int J Pharm 345:95-100.
215. Moran A, Buckton G. 2007. Adjusting and understanding the properties and crystallization behavior of amorphous trehalose as a function of spray drying feed concentration. Int J Pharm 343:12-17.
216. Toropainen T, Heikkilä T, Leppänen J, Matilainen L, Velaga S, Jarho P, Carlfors J, Lehto V-P, JäT, Järvinen K. 2007. Crystal structures of g-cyclodextrin after the SEDS process in supercritical carbon dioxide affect the dissolution rate of complexed budesonide. Pharm Res 24:1058-1066.
217. Liao X, Krishnamurthy R, Suryanarayanan R. 2007. Influence of processing conditions on the physical state of mannitol: Implications in freezedrying. Pharm Res 24:370-376.
218. Romero-Torres S, Wikström J, Grant ER, Taylor LS. 2007. Monitoring of mannitol phase behavior during freeze-drying using non-invasive Raman spectroscopy. PDA J Pharm Sci Tech 61:131-145.
219. Shibata Y, Fujii M, Kokudai M, Noda S, Okada H, Kondoh M, Watanabe Y. 2007. Effect of characteristics of compounds on maintenance of an amorphous state in solid dispersion with crospovidone. J Pharm Sci 96:1537-1547.
220. Shimpi S, Mahadik K, Takada K, Paradkar A. 2007. Application of polyglycolized glycerides in protection of amorphous form of etoricoxib during compression. Chem Pharm Bull 55:1448-1451.
221. Furlong PJ, Kelly CJ, Ogilvie RJ, Ryan V. 2007. Process. United States Patent 7,164,030: January 16, 2007.
222. Bombarda C, Dubini E, Ezhaya A, Schneider H, Schneider M. 2007. Stable polymorph of flibanserin. United States Patent 7,183,410: February 27, 2007.
223. Chemburkar SR, Patel K, Spiwek HO. 2007. Polymorph of a pharmaceutical. United States Patent 7,183,416: February 27, 2007.
224. Aher UP, Tarur VR, Sathe DG, Naidu AV, Sawant KD. 2007. Polymorph of (1-benzyl-4-[(5,6-dimethoxy-1-indanone)-2-y1] methyl piperidine hydrochloride (Donepezil hydrochloride) and a process for producing thereof. United States Patent 7,186,842: March 6, 2007.
225. Barkoczy J, Simig G, Greff Z, Nagy PK, Kirallyi ZS, Bartha F, Donath GV, Nagy K. 2007. Polymorphs of a 1-pyrrole derivative, intermediate for the preparation of atorvastatin. United States Patent 7,186,848: March 6, 2007.
226. Bonifacio F, Crescenzi C, Donnarumma M, Ippoliti D. 2007. Methods for preparing sertraline hydrochloride polymorphs. United States Patent 7,189,876: March 13, 2007.
227. Dahanukar VH, Nguyen HN, Orr CA, Zhang F, Zavialov IA, Klopfer K, Skell JM, Buchholz AW, Jr., Boyle CD. 2007. Xanthine phosphodiesterase V inhibitor polymorphs. United States Patent 7,192,962: March 20, 2007.
228. Werling J, Doty MJ, Rebbeck CL, Wong JCT, Kipp JE. 2007. Polymorphic form of itraconazole. United States Patent 7,193,084: March 20, 2007.
229. Morissette SL, Almarsson O, Soukasene S. 2007. Solvates and polymorphs of ritonavir and methods of making and using the same. United States Patent 7,205,413: April 17, 2007.
230. Bhandarkar S, Majuru S, Levchik H. 2007. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate. United States Patent 7,208,178: April 24, 2007.
231. Eble A, Sirges W, Schwiedop U, Heyn A. 2007. Method for producing specific crystalline modifications of polymorphous substances. United States Patent 7,211,697: May 1, 2007.
232. Kruk HT, McGee LR, Yang B. 2007. Salts and polymorphs of a potent antidiabetic compound. United States Patent 7,223,761: May 29, 2007.
233. Bhandarkar S, Majuru S, Levchik H. 2007. Polymorphs of sodium 4-[(4-chloro-2-hydroxybenzoyl) amino] butanoate. United States Patent 7,227,033: June 5, 2007.
234. Wu W. 2007. Crystalline polymorph of a bisulfate salt of a thrombin receptor antagonist. United States Patent 7,235,567: June 26, 2007.
235. Parthasaradhi RB, Rathnakar RK, Raji RR, Muralidhara RD, Chander RKS. 2007. Polymorphs of quetiapine fumarate. United States Patent 7,238,686: July 3, 2007.
236. Bhatarah P, McHattie D, Greenwood A, Hedger PCM. 2007. Preparation of cabergoline. United States Patent 7,238,810: July 3, 2007.
237. Filić D, Dumić M, Klepić B, Danilovski A, Tudja M. 2007. Polymorph V of torasemide. United States Patent 7,241,782: July 10, 2007.
238. Chebiyyam P, Mamillapalli RS, Krishnamurthi V, Seella VR, Gaddam OR. 2007. Polymorphic forms of 5-[4-[2-[n-methyl-n-(2-pyridyl)amino[ethoxy]-benzyl] thiazolidine-2,4-dione maleate and process for their preparation. United States Patent 7,241,895: July 10, 2007.
239. Boyer T, Day CJ, Whitehead AJ, Henson RA. 2007. Process for preparing a thiazole PPAR-ligand and polymorphs thereof. United States Patent 7,244,849: July 17, 2007.
240. Blasko A, Jin Q, Mauragis MA, Song D, Vonderwell BS. 2007. Salts and polymorphs of a pyrrole-substituted indolinone compound. United States Patent 7,247,627: July 24, 2007.
241. Keri V, Szabo C, Arval EN, Aronhime J. 2007. Forms of pravastatin sodium. United States Patent 7,262,218: August 28, 2007.
242. 4.9]-hexadeca-2(11) ,3,5,7-,9-pentaene and pharmaceutical compositions thereof. United States Patent 7,265,119: September 4, 2007.
243. Liu J, Nayyar N, Guo M, Wu Z-P, Borer BC, Srirangam AN, Mitchell MB, Li Y, Chu J-J. 2007. Polymorphic and amorphous forms of the phosphate salt of 8-fluoro-2-{4-[(methylamino)-methyl]phenyl}-1,3,4,5-tetrahydro-6H-azepino[-5, 4,3-ce]indol-6-one. United States Patent 7,268, 126: September 11, 2007.
244. Brittain HG, Dickason DA, Hotz J, Lyons SL, Ramstack M, Wright SG. 2007. Polymorphic forms of naltrexone. United States Patent 7,279,579: October 9, 2007.
245. Zhu T, Fawzi MB. 2007. Rapamycin polymorphs and uses thereof. United States Patent 7,282,505: October 16, 2007.
246. Patel HV, Ray AK, Patel PB, Patel MR. 2007. Process of preparation of olanzapine form I. United States Patent 7,297,789: November 20, 2007.
247. Parthasaradhi RB, Rathnakar RK, Raji RR, Muralidhara RD, Chander RKS. 2007. Polymorphs of imatinib mesylate. United States Patent 7,300,938: November 27, 2007.
248. Zook SE, Hettomger D. 2007. Hydrate of N-methyl-N-(3-{3-[2- thienylcarbonyl]-pyrazol-[1,5-α]-pyrimidin-7-yl}phenyl)acetamide and processes and methods related thereto. United States Patent 7,304,069: December 4, 2007.
249. Kubota H, Iwaoka K, Yamaguchi S, Yokota M. 2007. Crystals. United States Patent 7,309,710: December 18, 2007.